Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
Conditions
Interventions
Intervention1: MyVir tablets: Dosage Form: Tablet
Duration : Day 1 to Day 21
Route : Orally twice daily after meal
Control Intervention1: Standard treatment as per hospital protocol for COVID 19: Ca
Sponsors
MiLab LifeSciences P Ltd
Eligibility
Inclusion criteria
Inclusion criteria: 1. Subjects age group 18 - 65 years both gender 2. Patients diagnosed with COVID-19 positive mild symptomatic patients (Confirmed by RTPCR) - Patients with uncomplicated upper respiratory infection a. Spo2 >94% in room air b. Respiratory rate c. No evidence of hypoxaemia or breathlessness 3. Subjects willing to give a written informed consent and come for a regular follow up 4. Subject willing to abide by and comply with the study protocol
Exclusion criteria
Exclusion criteria: i.Presence of acute hypoxic respiratory failure. ii.Intensive care unit (ICU) stay. iii. Patients who need mechanical ventilation. iv.Category 6 or 5 based on modified 7-category ordinal scale of clinical status.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.RT PCR on Day 0,Day 7 and Day 10 2.LDH, TLC, CRP, D-DIMER and RT PCR from baseline to end of the study i.e. 14 days Timepoint: Day 1,Day 7,Day 10 and Day 14 | — |
Secondary
| Measure | Time frame |
|---|---|
| monitoring for adverse events and laboratory safety parametersTimepoint: Day 1 to Day 21 | — |
Countries
India
Contacts
Public ContactMrLAKSHMANA PERUMAL SPT
Mi Lab LifeSciences(P) Limited
Outcome results
None listed